This inventor holds 4 USPTO granted patents. Top assignees: Orion-Yhtyma Oy, Farmos Group Ltd., Risto Arvo Sakari Lammintausta. Active years: 1985-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 112 
1 out of 10 
1 out of 1 Years Active: 1985-1999
Title: **Marja-Liisa Sodervall: Pioneering Innovator in Aromatase Inhibition**
Introduction
Marja-Liisa Sodervall, based in Oulu, Finland, is a distinguished inventor known for her significant contributions to the field of pharmacology. With a portfolio that includes four patents, she has focused her research on developing selective aromatase inhibiting compounds, which play a crucial role in treating estrogen-dependent diseases like breast cancer and benign prostatic hyperplasia (BPH).
Latest Patents
One of her latest patents involves the formulation of selective aromatase inhibiting compounds. These compounds, characterized by a specific formula comprising various substituents such as heterocyclyl radicals and other functional groups, exhibit potent selective aromatase inhibiting properties. They are designed to provide therapeutic solutions while minimizing unwanted effects associated with desmolase inhibition. This innovation not only enhances treatment options for patients but also signifies a leap forward in targeted cancer therapies.
Career Highlights
Throughout her career, Marja-Liisa has made substantial contributions while working at notable companies, including Orion-yhtyma Oy, where she focused on advancing pharmacological research. Her work has advanced the understanding of aromatase inhibition and its applications in medical treatments. In addition to her role at Orion, Marja-Liisa has also collaborated with Risto Arvo Sakari Lammintausta, further expanding her influence in the field.
Collaborations
Collaboration has been a significant aspect of Marja-Liisa's career. She has partnered with talented researchers such as Arto J. Karjalainen and Arja Marketta Kalapudas, fostering a productive environment that promotes innovation and shared knowledge. These collaborations have allowed her to refine her inventions and develop even more effective therapeutic compounds.
Conclusion
Marja-Liisa Sodervall's innovative work in the development of selective aromatase inhibitors underscores her role as a leading inventor in the medical field. Her patents and contributions not only illustrate her expertise but also highlight the importance of collaboration in driving advancements in healthcare. As she continues her research, the potential for new treatments emerging from her work remains promising, offering hope for those affected by estrogen-dependent conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile